Lorant Leopold

883 total citations
14 papers, 663 citations indexed

About

Lorant Leopold is a scholar working on Epidemiology, Infectious Diseases and Pediatrics, Perinatology and Child Health. According to data from OpenAlex, Lorant Leopold has authored 14 papers receiving a total of 663 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Epidemiology, 8 papers in Infectious Diseases and 4 papers in Pediatrics, Perinatology and Child Health. Recurrent topics in Lorant Leopold's work include Influenza Virus Research Studies (7 papers), Respiratory viral infections research (7 papers) and HIV/AIDS drug development and treatment (6 papers). Lorant Leopold is often cited by papers focused on Influenza Virus Research Studies (7 papers), Respiratory viral infections research (7 papers) and HIV/AIDS drug development and treatment (6 papers). Lorant Leopold collaborates with scholars based in United States, Belgium and France. Lorant Leopold's co-authors include Johan Vingerhoets, Goedele De Smedt, Monika Peeters, Brian Woodfall, Timothy Wilkin, Pedro Cahn, Richard Haubrich, Beatriz Grinsztejn, Gilles Pialoux and José Valdez Madruga and has published in prestigious journals such as The Lancet, The Journal of Infectious Diseases and Clinical Pharmacology & Therapeutics.

In The Last Decade

Lorant Leopold

14 papers receiving 627 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Lorant Leopold United States 9 500 347 258 86 54 14 663
Hamid Hasson Italy 13 468 0.9× 345 1.0× 224 0.9× 49 0.6× 142 2.6× 69 792
Esther Race France 15 957 1.9× 915 2.6× 117 0.5× 81 0.9× 47 0.9× 19 1.1k
Ben Van Baelen United States 10 622 1.2× 296 0.9× 373 1.4× 83 1.0× 37 0.7× 13 826
Gong Shen United States 11 349 0.7× 113 0.3× 167 0.6× 86 1.0× 30 0.6× 21 516
Jeffrey S. Murray United States 13 355 0.7× 218 0.6× 322 1.2× 72 0.8× 61 1.1× 31 729
Diane Bollens France 10 392 0.8× 279 0.8× 171 0.7× 16 0.2× 74 1.4× 18 476
Judith Millard United States 10 534 1.1× 410 1.2× 118 0.5× 29 0.3× 84 1.6× 15 647
Rujuta A. Bam United States 8 471 0.9× 379 1.1× 135 0.5× 141 1.6× 92 1.7× 11 609
Helen Steel United Kingdom 10 305 0.6× 208 0.6× 157 0.6× 46 0.5× 74 1.4× 12 626
Mohammed Janabi Tanzania 9 216 0.4× 119 0.3× 81 0.3× 50 0.6× 28 0.5× 15 412

Countries citing papers authored by Lorant Leopold

Since Specialization
Citations

This map shows the geographic impact of Lorant Leopold's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Lorant Leopold with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Lorant Leopold more than expected).

Fields of papers citing papers by Lorant Leopold

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Lorant Leopold. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Lorant Leopold. The network helps show where Lorant Leopold may publish in the future.

Co-authorship network of co-authors of Lorant Leopold

This figure shows the co-authorship network connecting the top 25 collaborators of Lorant Leopold. A scholar is included among the top collaborators of Lorant Leopold based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Lorant Leopold. Lorant Leopold is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

14 of 14 papers shown
1.
Leopold, Lorant, Johan Vingerhoets, Karin Weber, et al.. (2024). Efficacy and Safety of Pimodivir Combined With Standard of Care in Hospitalized and Nonhospitalized High-Risk Adolescents and Adults With Influenza A Infection. The Journal of Infectious Diseases. 231(1). e132–e143. 3 indexed citations
2.
Vingerhoets, Johan, Ilse Van Dromme, Wilbert van Duijnhoven, et al.. (2023). Genotypic and phenotypic characterization of influenza A viral variants in study participants treated with pimodivir in the phase 2b TOPAZ study. Antiviral Therapy. 28(3). 211900033–211900033. 3 indexed citations
3.
Duijnhoven, Wilbert van, et al.. (2022). The Hospital Recovery Scale: A clinically useful endpoint in patients hospitalized with influenza. Contemporary Clinical Trials. 123. 106952–106952. 5 indexed citations
4.
O’Neil, Brian J., Michael G. Ison, Anna Nilsson, et al.. (2020). A Phase 2 Study of Pimodivir (JNJ-63623872) in Combination With Oseltamivir in Elderly and Nonelderly Adults Hospitalized With Influenza A Infection: OPAL Study. The Journal of Infectious Diseases. 226(1). 109–118. 22 indexed citations
5.
Finberg, Robert W., David Anderson, Roman Fleischhackl, et al.. (2018). Phase 2b Study of Pimodivir (JNJ-63623872) as Monotherapy or in Combination With Oseltamivir for Treatment of Acute Uncomplicated Seasonal Influenza A: TOPAZ Trial. The Journal of Infectious Diseases. 219(7). 1026–1034. 87 indexed citations
6.
7.
Trevejo, José, Mohammed Asmal, Johan Vingerhoets, et al.. (2017). Pimodivir Treatment in Adult Volunteers Experimentally Inoculated with Live Influenza Virus: A Phase IIa, Randomized, Double-Blind, Placebo-Controlled Study. Antiviral Therapy. 23(4). 335–344. 45 indexed citations
8.
Kakuda, Thomas N., Lorant Leopold, Maarten Timmers, et al.. (2014). Bioavailability and bioequivalence of a darunavir 800-mg tablet formulation compared with the 400-mg tablet formulation. International Journal of Clinical Pharmacology and Therapeutics. 52(9). 805–816. 6 indexed citations
9.
Kakuda, Thomas N., Lorant Leopold, Steven Nijs, et al.. (2014). Pharmacokinetic interaction between etravirine or rilpivirine and telaprevir in healthy volunteers: A randomized, two-way crossover trial. The Journal of Clinical Pharmacology. 54(5). 563–573. 10 indexed citations
10.
Kakuda, Thomas N., et al.. (2013). The effect of single- and multiple-dose etravirine on a drug cocktail of representative cytochrome P450 probes and digoxin in healthy subjects. The Journal of Clinical Pharmacology. 54(4). 422–431. 15 indexed citations
11.
Kakuda, Thomas N., Goedele De Smedt, Lorant Leopold, et al.. (2013). Single-dose pharmacokinetics of pediatric and adult formulations of etravirine and swallowability of the 200-mg tablet: results from three Phase 1 studies. International Journal of Clinical Pharmacology and Therapeutics. 51(9). 725–736. 8 indexed citations
12.
Kakuda, Thomas N., Janet R. Wade, Eric Snoeck, et al.. (2010). Pharmacokinetics and Pharmacodynamics of the Non-Nucleoside Reverse-Transcriptase Inhibitor Etravirine in Treatment-Experienced HIV-1-Infected Patients. Clinical Pharmacology & Therapeutics. 88(5). 695–703. 37 indexed citations
13.
Kakuda, Thomas N., Monika Peeters, Chris Corbett, et al.. (2008). Pharmacokinetics (PK) and Pharmacodynamics (PD) of Etravirine (ETR) in Treatment-Experienced HIV-1 Infected Patients: Pooled 48-Week Results of DUET-1 and DUET-2. 46th Annual Meeting. 5 indexed citations
14.
Madruga, José Valdez, Pedro Cahn, Beatriz Grinsztejn, et al.. (2007). Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-1: 24-week results from a randomised, double-blind, placebo-controlled trial. The Lancet. 370(9581). 29–38. 403 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Hamid Hasson Breakdown of academic impact, for papers by Esther Race Breakdown of academic impact, for papers by Ben Van Baelen Breakdown of academic impact, for papers by Gong Shen Breakdown of academic impact, for papers by Jeffrey S. Murray Breakdown of academic impact, for papers by Diane Bollens Breakdown of academic impact, for papers by Judith Millard Breakdown of academic impact, for papers by Rujuta A. Bam Breakdown of academic impact, for papers by Helen Steel Breakdown of academic impact, for papers by Mohammed Janabi
Rankless by CCL
2026